Stock Track | Tyra Biosciences Soars 5.27% as Phase 2 Trial for Pediatric Achondroplasia Drug Begins

Stock Track08-21

Shares of Tyra Biosciences, Inc. (TYRA) are soaring 5.27% in Thursday's trading session following the announcement that the company has dosed the first child in its Phase 2 clinical study for dabogratinib, a potential treatment for pediatric achondroplasia. This significant milestone has sparked investor interest in the clinical-stage biotechnology company.

The Phase 2 study, known as BEACH301, aims to evaluate the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism. Dabogratinib, developed using Tyra's SNÅP platform, is a once-daily oral FGFR3-selective inhibitor. Notably, it is currently the only oral FGFR3-selective inhibitor in clinical development for achondroplasia, potentially positioning Tyra Biosciences at the forefront of treatment options for this condition.

This development marks a crucial step forward in Tyra Biosciences' efforts to address unmet medical needs in skeletal dysplasia. While the initial results from the safety sentinel cohort are not expected until the second half of 2026, the commencement of the trial itself is seen as a positive indicator of the company's progress. Investors appear optimistic about the potential of dabogratinib and its impact on Tyra Biosciences' future prospects, as reflected in today's stock price surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185651858?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-21 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185651858","market":"us","top_or_hot":-1,"title":"Stock Track | Tyra Biosciences Soars 5.27% as Phase 2 Trial for Pediatric Achondroplasia Drug Begins","media":"Stock Track","content":"<p>Shares of Tyra Biosciences, Inc. (TYRA) are soaring 5.27% in Thursday's trading session following the announcement that the company has dosed the first child in its Phase 2 clinical study for dabogratinib, a potential treatment for pediatric achondroplasia. This significant milestone has sparked investor interest in the clinical-stage biotechnology company.</p>\n\n<p>The Phase 2 study, known as BEACH301, aims to evaluate the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism. Dabogratinib, developed using Tyra's SNÅP platform, is a once-daily oral FGFR3-selective inhibitor. Notably, it is currently the only oral FGFR3-selective inhibitor in clinical development for achondroplasia, potentially positioning Tyra Biosciences at the forefront of treatment options for this condition.</p>\n\n<p>This development marks a crucial step forward in Tyra Biosciences' efforts to address unmet medical needs in skeletal dysplasia. While the initial results from the safety sentinel cohort are not expected until the second half of 2026, the commencement of the trial itself is seen as a positive indicator of the company's progress. Investors appear optimistic about the potential of dabogratinib and its impact on Tyra Biosciences' future prospects, as reflected in today's stock price surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tyra Biosciences Soars 5.27% as Phase 2 Trial for Pediatric Achondroplasia Drug Begins</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tyra Biosciences Soars 5.27% as Phase 2 Trial for Pediatric Achondroplasia Drug Begins\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-21 22:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Tyra Biosciences, Inc. (TYRA) are soaring 5.27% in Thursday's trading session following the announcement that the company has dosed the first child in its Phase 2 clinical study for dabogratinib, a potential treatment for pediatric achondroplasia. This significant milestone has sparked investor interest in the clinical-stage biotechnology company.</p>\n\n<p>The Phase 2 study, known as BEACH301, aims to evaluate the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism. Dabogratinib, developed using Tyra's SNÅP platform, is a once-daily oral FGFR3-selective inhibitor. Notably, it is currently the only oral FGFR3-selective inhibitor in clinical development for achondroplasia, potentially positioning Tyra Biosciences at the forefront of treatment options for this condition.</p>\n\n<p>This development marks a crucial step forward in Tyra Biosciences' efforts to address unmet medical needs in skeletal dysplasia. While the initial results from the safety sentinel cohort are not expected until the second half of 2026, the commencement of the trial itself is seen as a positive indicator of the company's progress. Investors appear optimistic about the potential of dabogratinib and its impact on Tyra Biosciences' future prospects, as reflected in today's stock price surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TYRA","symbol_name":"Tyra Biosciences, Inc.","start_time":0,"source_url":"","article_id":"1185651858","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185651858","pubTimestamp":1755786041,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Tyra Biosciences, Inc. (TYRA) are soaring 5.27% in Thursday's trading session following the announcement that the company has dosed the first child in its Phase 2 clinical study for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TYRA":"Tyra Biosciences, Inc."},"translate_title":"个股追踪|Tyra Biosciences飙升5.27%儿科软骨发育不全药物2期试验开始","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TYRA":1},"content_text":"Shares of Tyra Biosciences, Inc. (TYRA) are soaring 5.27% in Thursday's trading session following the announcement that the company has dosed the first child in its Phase 2 clinical study for dabogratinib, a potential treatment for pediatric achondroplasia. This significant milestone has sparked investor interest in the clinical-stage biotechnology company.\nThe Phase 2 study, known as BEACH301, aims to evaluate the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism. Dabogratinib, developed using Tyra's SNÅP platform, is a once-daily oral FGFR3-selective inhibitor. Notably, it is currently the only oral FGFR3-selective inhibitor in clinical development for achondroplasia, potentially positioning Tyra Biosciences at the forefront of treatment options for this condition.\nThis development marks a crucial step forward in Tyra Biosciences' efforts to address unmet medical needs in skeletal dysplasia. While the initial results from the safety sentinel cohort are not expected until the second half of 2026, the commencement of the trial itself is seen as a positive indicator of the company's progress. Investors appear optimistic about the potential of dabogratinib and its impact on Tyra Biosciences' future prospects, as reflected in today's stock price surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185651858","isCrawlerRequest":true}